Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genticel Appoints New Vice-President

Published: Friday, November 08, 2013
Last Updated: Friday, November 08, 2013
Bookmark and Share
Appointment of Dr Gerald Moeller as vice-president of Company’s supervisory board.

Genticel has appointed a new vice-president to the supervisory board.

Dr Gerald Moeller, PhD has over 35 years experience in the pharmaceutical and diagnostics industry. He has been an investment adviser at HBM Partners in Switzerland since 2002 and chairs the supervisory boards of a number of health sector companies, including 4Sigma Ltd, Definiens AG, Invendo-Medical GmbH and MorphoSys AG. He is also a board member with FIND Foundation and Illumina Inc.

"We are very pleased that Dr Moeller is joining our supervisory board,” says Benedikt Timmerman, founder and CEO of Genticel. “His wealth of expertise in the pharmaceutical industry represents a considerable asset for Genticel, especially at a key moment in our development. We are launching the phase II clinical trial of our lead product, ProCervix, in Europe - so it is a priority for Genticel to forge close ties with major pharmaceutical industry players. Gerry's experience in this industry and his strategic advice will be invaluable in this."

"The results of the phase I trial of ProCervix are very encouraging. It is the first vaccine to meet the medical needs of over 90 million women infected with HPV16 and/or 18," says Dr Gerald Moeller. "I am delighted to help Genticel reap the benefits of such promising projects."

The supervisory board at Genticel is chaired by Professor Thierry Hercend. The membership comprises Ludovic de Meeus d'Argenteuil, co-founder of Genticel; Alain Munoz, representing Kurma Life Sciences; Raphael Wisniewski, director of investment at Edmond de Rothschild Investment Partners (EdRIP); Olivier Martinez, director of investment, life sciences, BPI France; Alexandre Flageul, partner at Amundi Private Equity Funds; and Dr Didier Hoch, an independent industry member.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genticel Announces Positive Preclinical Proof of Concept Results of GTL002
Based on Company's versatile Vaxiclase platform.
Tuesday, June 02, 2015
Genticel Completes Procervix Phase II Study Enrollment Ahead of Schedule
A total of 239 subjects infected with HPV 16 and/or 18 enrolled at 39 clinical centers throughout Europe for RHEIA-VAC study of ProCervix.
Saturday, November 15, 2014
Genticel: Business Update - Third Quarter 2014
Net cash and equivalents of €35.2 million as of September 30, 2014.
Tuesday, November 04, 2014
Mary Tanner Appointed to Genticel’s Supervisory Board
Ms. Tanner appointed as independently-acting member and as Audit Committee chairman.
Tuesday, October 07, 2014
Genticel’s Phase II Study with ProCervix Passes the Halfway Mark for Patient Recruitment
The trial is proceeding as planned, after first DSMB (Data and Safety Monitoring Board) review.
Friday, July 18, 2014
Genticel Launches its Phase II Trial in Women Infected with High-Risk HPV
The appointment of Dr. Sophie Olivier as chief medical officer completes the Genticel team to run the Phase II trial across Europe.
Thursday, March 06, 2014
Genticel Secures EUR 18.2 Million (USD 23.7 million) in Capital Funding
Dr. Rainer Strohmenger joins the supervisory board of Genticel.
Friday, April 26, 2013
Genticel Announces Positive Data from Phase I Trial in HPV Infected Women
First ever trial to recruit HPV infected women with no cervical lesions.
Tuesday, April 16, 2013
Genticel Completed Recruitment for its Phase Ib Vaccine Trial in HPV Infected Women
Company expects the final results before the end of the second quarter 2012.
Wednesday, February 22, 2012
Genticel Completes Patient Recruitment for its Phase I Trial with ProCervix
Company expects to complete its full Phase I Program in the first half of 2012.
Thursday, October 20, 2011
Scientific News
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Refuelling the Cancer Fight
Scientists have discovered that the microenvironment supporting cancer tumors starves immune cells of 'fuel', preventing tumour destruction.
Obesity Inhibits Influenza Vaccine Response
Researchers have shown that obesity in mice has detrimental effect on influenza vaccine response.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!